drug_type
RELEVANT_DRUG
intervention_type
Drug (antibody-drug conjugate)
drug_description
HER2-targeted antibody–drug conjugate composed of a humanized anti‑HER2 IgG1 (trastuzumab) linked via a cleavable linker to the topoisomerase I inhibitor payload deruxtecan (DXd); binds HER2, internalizes, releases DXd to inhibit topoisomerase I and induce DNA damage; also inhibits HER2 signaling and mediates ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Trastuzumab Deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-targeted ADC: a humanized anti-HER2 IgG1 (trastuzumab) delivers a cleavable linker–attached topoisomerase I inhibitor (deruxtecan, DXd). Upon HER2 binding and internalization, lysosomal cleavage releases DXd to inhibit topoisomerase I, causing DNA damage and cell death; the membrane-permeable payload enables a bystander effect. The antibody also inhibits HER2 signaling and mediates ADCC.
drug_name
Trastuzumab deruxtecan (DS-8201; T-DXd)
nct_id_drug_ref
NCT06945224